Claire Carman, MD
General Surgery · Norfolk, VANPI 1982641700
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,038 of the $13,155 with a category attached, or 68.7%. Myriad Genetic Laboratories, Inc. accounts for 90.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $9,531 and has fallen 89.0% since, to $1,047 in 2024. Among general surgery clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 45 payments — averaging $292.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Genetic Laboratories, Inc.$12K
- Leica Microsystems Inc.$353
- Mentor Worldwide LLC$333
- Merck$149
- Pfizer$123
- AstraZeneca$110
- plus $172 from 2 others
What the payments were for
- Consulting fees$1,35010%
- Speaking & faculty fees$9,03869%
- Food & beverage$2,76821%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myriad Genetic Laboratories, Inc. | 27 | $11,916 |
| Leica Microsystems Inc. | 9 | $353 |
| Mentor Worldwide LLC | 3 | $333 |
| Merck | 2 | $149 |
| Pfizer | 1 | $123 |
| AstraZeneca | 1 | $110 |
| AbbVie | 1 | $107 |
| Stryker | 1 | $65 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- myRisk$9,437
- myChoice CDx$2,300
- FlexHD Acellular Hydrated Dermis$126
- MemoryGel Breast Implants$126
- KEYTRUDA$124
- IBRANCE$123
- ARTOURA Breast Tissue Expander$117
- PreciseTumor$110
- LYNPARZA$110
- NATRELLE$107
How this compares
$13,155 in reported general payments places this provider in the 95th percentile of 40 general surgery providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Raloxifene Hcl | 12 | $1,075 |
| Nystatin-TriamcinoloneNystatin/Triamcinolone Acet | 13 | $296 |
| Lorazepam | 26 | $32 |
Paid to pharmacies, not to this prescriber.
Other general surgery in Norfolk
- George HubbardNorfolk$709
- Virginia StewartNorfolk$0
- Richard WrightNorfolk$0
- James SnyderNorfolk$0
- Matthew BrengmanRichmond$156K
- Gregory SchroderRichmond$12K
- Basil SkenderisVirginia Beach$12K
- Beryl BrownVirginia Beach$3K
- Anthony TerracinaNewport News$2K
- Jeffrey BergerVirginia Beach$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.